-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: David Thomas, CFA
David is currently Director of Industry Research and Analysis at BIO in Washington, DC. In this role, he is responsible for financial statistics and analysis of the biotechnology sector and contributes to BIO’s policy activities as well as programming for BIO’s investor conferences. Prior to joining BIO, he was a research scientist at the J. Craig Venter Institute working on the “synthetic cell” team led by Nobel Laureate Hamilton Smith. Before his role in synthetic biology, David worked as a scientist in drug discovery at Amgen, Millennium, and Novartis. His scientific expertise is in protein engineering, enzymology, and synthetic biology. David has earned the Chartered Financial Analyst (CFA) designation and holds a master’s degree in biochemistry.
Latest Posts
2011, The Year of Positive Thinking? BIO/IPREO Study Reveals High Hopes for the Industry
BIO CEO’s closing plenary session featured plenty of crystal ball gazing and candid quips about what 2011 has in store for the biotech industry. While the panel provided an in-depth look at how buy-side and sell-side analysts evaluate the industry, the BIO/IPREO Investor Perception Study reveals that the majority of investors believe biotech is headed in the right direction. Access full study deck here: BIO CEO – IPREO Biotech Investor Perception Study The study also reveals that Read More >
Release of BIO/Biomedtracker Drug Approval Rates Study
BIO and BioMedTracker are pleased to present the findings of their joint clinical trial success rates study. Using clinical trial data from the past seven years, this analysis examines the most recent probability of success by treatment type, phase of development and therapeutic area. The overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2010 is near one in 10, not one in five to one Read More >
Effective Tax Rates for Biotech
The New York Times published a misleading article and companion blog post on corporate tax rates last Thursday, leaving us scratching our heads over the claim that the biotech sector pays a paltry “effective” corporate tax rate of 4.46%, the lowest rate amongst the 20 industries surveyed. After careful reading of the article and examination of supporting documents, we found that the authors vastly underestimated the industry’s effective tax rate. First, the authors incorrectly average Read More >
2010 Biotech Stock Performance
How did biotech stocks perform in 2010? It was a good year for the two most closely followed biotech stock indices, the NBI and BTK, as each outperformed the S&P 500 in 2010. However, in terms of breadth, only 49% of companies posted a gain for 2010 as seen in the first chart below. The 92 companies that started the year in the valuation range of $1M-$50M had a median return of -8%, a reversal Read More >
IPO UPDATE – JANUARY 4th, 2011
In 2010 we saw the return of the Biotech IPO. In the US, 17 biotech companies went public, up from 3 in 2009, and only 1 in 2008. However, almost all of them had to accept a lower price than was sought in the initial filing. The average downward adjustment to the amount raised was 25%. The median and mean amount raised in the US in 2010 was $53M and $84M, respectively. Since the IPO Read More >
